PT3182128T - Cinase ros em cancro do pulmão - Google Patents
Cinase ros em cancro do pulmãoInfo
- Publication number
- PT3182128T PT3182128T PT16196573T PT16196573T PT3182128T PT 3182128 T PT3182128 T PT 3182128T PT 16196573 T PT16196573 T PT 16196573T PT 16196573 T PT16196573 T PT 16196573T PT 3182128 T PT3182128 T PT 3182128T
- Authority
- PT
- Portugal
- Prior art keywords
- lung cancer
- ros kinase
- ros
- kinase
- lung
- Prior art date
Links
Classifications
-
- G01N33/5752—
-
- G01N33/575—
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57407—Specifically defined cancers
- G01N33/57423—Specifically defined cancers of lung
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
- C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/156—Polymorphic or mutational markers
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/90—Enzymes; Proenzymes
- G01N2333/91—Transferases (2.)
- G01N2333/912—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Immunology (AREA)
- General Health & Medical Sciences (AREA)
- Analytical Chemistry (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Pathology (AREA)
- Biochemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biotechnology (AREA)
- Physics & Mathematics (AREA)
- Microbiology (AREA)
- Medicinal Chemistry (AREA)
- Biophysics (AREA)
- Oncology (AREA)
- Hospice & Palliative Care (AREA)
- General Engineering & Computer Science (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Biomedical Technology (AREA)
- Cell Biology (AREA)
- Food Science & Technology (AREA)
- General Physics & Mathematics (AREA)
- Pulmonology (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US13/113,676 US20120208824A1 (en) | 2006-01-20 | 2011-05-23 | ROS Kinase in Lung Cancer |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PT3182128T true PT3182128T (pt) | 2019-03-14 |
Family
ID=46208827
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PT16196573T PT3182128T (pt) | 2011-05-23 | 2012-05-23 | Cinase ros em cancro do pulmão |
Country Status (13)
| Country | Link |
|---|---|
| US (3) | US20120208824A1 (enExample) |
| EP (3) | EP3492918B1 (enExample) |
| JP (3) | JP6210977B2 (enExample) |
| KR (1) | KR102123963B1 (enExample) |
| CN (2) | CN103858011B (enExample) |
| CA (2) | CA2841900C (enExample) |
| DK (2) | DK2715365T3 (enExample) |
| ES (2) | ES2611281T3 (enExample) |
| HU (1) | HUE041780T2 (enExample) |
| PT (1) | PT3182128T (enExample) |
| SI (1) | SI3182128T1 (enExample) |
| TR (1) | TR201902690T4 (enExample) |
| WO (1) | WO2012162373A1 (enExample) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20120208824A1 (en) | 2006-01-20 | 2012-08-16 | Cell Signaling Technology, Inc. | ROS Kinase in Lung Cancer |
| AU2010213578B2 (en) * | 2009-02-12 | 2015-01-29 | Cell Signaling Technology, Inc. | Mutant ROS expression in human cancer |
| WO2014146139A2 (en) * | 2013-03-15 | 2014-09-18 | Expression Pathology, Inc. | Srm assay to indicate cancer therapy |
| CN106164676B (zh) * | 2014-01-06 | 2019-07-05 | 爱科谱迅病理研究公司 | 针对pd-l1的srm测定 |
| WO2017153932A1 (en) | 2016-03-10 | 2017-09-14 | Novartis Ag | Strn-alk fusion as a therapeutic target in gastric cancer |
| WO2017175111A1 (en) | 2016-04-04 | 2017-10-12 | Novartis Ag | Strn-alk fusion as a therapeutic target in colorectal cancer |
| CA3055109A1 (en) * | 2017-03-08 | 2018-09-13 | Ariad Pharmaceuticals, Inc. | Pharmaceutical formulations comprising 5-chloro-n4-[2-(dimethylphosphoryl)phenyl]-n2-{2-methoxy-4-[4-(4-methylpiperazin-1-yl)piperidin-1-yl]phenyl}pyrimidine-2,4-diamine |
| KR101987065B1 (ko) * | 2017-08-07 | 2019-06-10 | 주식회사 싸이토젠 | Eml4-alk유전자 변이 분석방법 |
| KR102167739B1 (ko) | 2018-10-31 | 2020-10-19 | 한국과학기술연구원 | Alk 또는 ros-1 인산화 효소 억제제 스크리닝을 위한 방법, 조성물 및 키트 및 방법 |
| JP7313033B2 (ja) * | 2019-03-01 | 2023-07-24 | 国立大学法人北海道大学 | Ｉｋｚｆ１遺伝子変異を検出するための核酸プローブセット及び当該プローブセットを用いたｉｋｚｆ１遺伝子変異の検出方法 |
| CN110632318B (zh) * | 2019-10-28 | 2023-04-07 | 四川大学华西医院 | Tpm3自身抗体检测试剂在制备肺癌筛查试剂盒中的用途 |
| CN111440241B (zh) * | 2020-05-31 | 2021-01-05 | 广东赛尔生物科技有限公司 | 一种包含特异性结合ros1的单克隆抗体的癌症检测试剂盒 |
Family Cites Families (87)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE3023787A1 (de) | 1980-06-25 | 1982-01-21 | Studiengesellschaft Kohle mbH, 4330 Mülheim | Verfahren zur erhoehung der inkorporation und der expression von genetischem material in die kerne von intakten zellen mit hilfe von liposomen |
| US4376110A (en) | 1980-08-04 | 1983-03-08 | Hybritech, Incorporated | Immunometric assays using monoclonal antibodies |
| US4474893A (en) | 1981-07-01 | 1984-10-02 | The University of Texas System Cancer Center | Recombinant monoclonal antibodies |
| US4522811A (en) | 1982-07-08 | 1985-06-11 | Syntex (U.S.A.) Inc. | Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides |
| US4659678A (en) | 1982-09-29 | 1987-04-21 | Serono Diagnostics Limited | Immunoassay of antigens |
| NZ207394A (en) | 1983-03-08 | 1987-03-06 | Commw Serum Lab Commission | Detecting or determining sequence of amino acids |
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| US4727022A (en) | 1984-03-14 | 1988-02-23 | Syntex (U.S.A.) Inc. | Methods for modulating ligand-receptor interactions and their application |
| JPH07119760B2 (ja) | 1984-07-24 | 1995-12-20 | コモンウエルス・セ−ラム・ラボラトリ−ズ・コミッション | ミモトープを検出または決定する方法 |
| US4676980A (en) | 1985-09-23 | 1987-06-30 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Target specific cross-linked heteroantibodies |
| US5756696A (en) | 1986-01-16 | 1998-05-26 | Regents Of The University Of California | Compositions for chromosome-specific staining |
| US5447841A (en) | 1986-01-16 | 1995-09-05 | The Regents Of The Univ. Of California | Methods for chromosome-specific staining |
| US5225539A (en) | 1986-03-27 | 1993-07-06 | Medical Research Council | Recombinant altered antibodies and methods of making altered antibodies |
| US6548640B1 (en) | 1986-03-27 | 2003-04-15 | Btg International Limited | Altered antibodies |
| US6121424A (en) | 1991-11-25 | 2000-09-19 | Enzon, Inc. | Multivalent antigen-binding proteins |
| US5260203A (en) | 1986-09-02 | 1993-11-09 | Enzon, Inc. | Single polypeptide chain binding molecules |
| US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
| EP0394827A1 (en) | 1989-04-26 | 1990-10-31 | F. Hoffmann-La Roche Ag | Chimaeric CD4-immunoglobulin polypeptides |
| EP0800830A3 (en) | 1989-11-03 | 1999-03-17 | Vanderbilt University | Method of in vivo delivery of functioning foreign genes |
| CA2050918A1 (en) | 1990-01-12 | 1991-07-13 | Raju Kucherlapati | Generation of xenogeneic antibodies |
| US6150584A (en) | 1990-01-12 | 2000-11-21 | Abgenix, Inc. | Human antibodies derived from immunized xenomice |
| DE4002897A1 (de) | 1990-02-01 | 1991-08-08 | Behringwerke Ag | Herstellung und verwendung von genbanken synthetischer menschlicher antikoerper ("synthetische human-antikoerper-bibliotheken") |
| EP0440147B2 (de) | 1990-02-01 | 2014-05-14 | Siemens Healthcare Diagnostics Products GmbH | Herstellung und Verwendung von Genbanken menschlicher Antikörper ("Human-Antikörper-Bibliotheken") |
| US5427908A (en) | 1990-05-01 | 1995-06-27 | Affymax Technologies N.V. | Recombinant library screening methods |
| GB9015198D0 (en) | 1990-07-10 | 1990-08-29 | Brien Caroline J O | Binding substance |
| US5545806A (en) | 1990-08-29 | 1996-08-13 | Genpharm International, Inc. | Ransgenic non-human animals for producing heterologous antibodies |
| US5491224A (en) | 1990-09-20 | 1996-02-13 | Bittner; Michael L. | Direct label transaminated DNA probe compositions for chromosome identification and methods for their manufacture |
| AU675916B2 (en) | 1991-06-14 | 1997-02-27 | Genentech Inc. | Method for making humanized antibodies |
| US5565332A (en) | 1991-09-23 | 1996-10-15 | Medical Research Council | Production of chimeric antibodies - a combinatorial approach |
| JPH07503132A (ja) | 1991-12-17 | 1995-04-06 | ジェンファーム インターナショナル，インコーポレイティド | 異種抗体を産生することができるトランスジェニック非ヒト動物 |
| JPH07509133A (ja) | 1992-07-17 | 1995-10-12 | リボザイム・ファーマシューティカルズ・インコーポレイテッド | 動物疾患の処置のための方法および剤 |
| US6710174B2 (en) | 2001-09-13 | 2004-03-23 | Isis Pharmaceuticals, Inc. | Antisense inhibition of vascular endothelial growth factor receptor-1 expression |
| IL108367A0 (en) | 1993-01-27 | 1994-04-12 | Hektoen Inst For Medical Resea | Antisense polynzcleotide inhibition of human growth factor-sensitive cancer cells |
| US6340674B1 (en) | 1993-03-26 | 2002-01-22 | Thomas Jefferson University | Method of inhibiting the proliferation and causing the differentiation of cells with IGF-1 receptor antisense oligonucleotides |
| US5480971A (en) | 1993-06-17 | 1996-01-02 | Houghten Pharmaceuticals, Inc. | Peralkylated oligopeptide mixtures |
| US5529925A (en) | 1993-12-03 | 1996-06-25 | St. Jude Children's Research Hospital | Nucleic acid sequences and fusion proteins present in human t(2;5) lymphoma |
| EP1231268B1 (en) | 1994-01-31 | 2005-07-27 | Trustees Of Boston University | Polyclonal antibody libraries |
| US6074642A (en) | 1994-05-02 | 2000-06-13 | Alexion Pharmaceuticals, Inc. | Use of antibodies specific to human complement component C5 for the treatment of glomerulonephritis |
| US5820873A (en) | 1994-09-30 | 1998-10-13 | The University Of British Columbia | Polyethylene glycol modified ceramide lipids and liposome uses thereof |
| US5753613A (en) | 1994-09-30 | 1998-05-19 | Inex Pharmaceuticals Corporation | Compositions for the introduction of polyanionic materials into cells |
| US5885613A (en) | 1994-09-30 | 1999-03-23 | The University Of British Columbia | Bilayer stabilizing components and their use in forming programmable fusogenic liposomes |
| US5783683A (en) | 1995-01-10 | 1998-07-21 | Genta Inc. | Antisense oligonucleotides which reduce expression of the FGFRI gene |
| US5675063A (en) | 1995-02-28 | 1997-10-07 | Loyola University Of Chicago | Immortalized rabbit hybridoma fusion partner |
| DE69621940T2 (de) | 1995-08-18 | 2003-01-16 | Morphosys Ag | Protein-/(poly)peptidbibliotheken |
| US6395713B1 (en) | 1997-07-23 | 2002-05-28 | Ribozyme Pharmaceuticals, Inc. | Compositions for the delivery of negatively charged molecules |
| US6617162B2 (en) | 2001-12-18 | 2003-09-09 | Isis Pharmaceuticals, Inc. | Antisense modulation of estrogen receptor alpha expression |
| EP1038016A2 (en) | 1997-12-16 | 2000-09-27 | Valentis Inc. | Needle-free injection of formulated nucleic acid molecules |
| US7300753B2 (en) | 1998-09-04 | 2007-11-27 | John Rush | Immunoaffinity isolation of modified peptides from complex mixtures |
| US7198896B2 (en) | 1998-09-04 | 2007-04-03 | Cell Signaling Technology, Inc. | Immunoaffinity isolation of modified peptides from complex mixtures |
| US6573043B1 (en) | 1998-10-07 | 2003-06-03 | Genentech, Inc. | Tissue analysis and kits therefor |
| ATE408699T1 (de) | 1999-03-10 | 2008-10-15 | Phogen Ltd | Verabreichung von nukleinsäuren und proteinen an zellen |
| US7662793B2 (en) | 1999-06-18 | 2010-02-16 | University Of Pittsburgh Of The Commonwealth System Of Higher Education | Inhibition of human squamous cell carcinoma growth in vivo by epidermal growth factor receptor antisense RNA transcribed from a Pol III promoter |
| US7829693B2 (en) | 1999-11-24 | 2010-11-09 | Alnylam Pharmaceuticals, Inc. | Compositions and methods for inhibiting expression of a target gene |
| KR101215789B1 (ko) | 2000-03-30 | 2012-12-26 | 화이트헤드 인스티튜트 포 바이오메디칼 리서치 | Ｒｎａ 간섭의 ｒｎａ 서열 특이적인 매개체 |
| DE60142691D1 (de) | 2000-09-09 | 2010-09-09 | Univ New York State Res Found | Verfahren und zusammensetzungen zur isolierung von metastatischen krebszellen und anwendung zur messung des metastatischen potentials eines krebses |
| SI1407044T2 (en) | 2000-12-01 | 2018-03-30 | Max-Planck-Gesellschaft Zur Forderung Der Wissenschaften E.V. | Rna interference mediating small rna molecules |
| JP2004531217A (ja) | 2001-01-05 | 2004-10-14 | ファイザー・インク | インスリン様成長因子ｉ受容体に対する抗体 |
| WO2002095059A2 (en) | 2001-05-17 | 2002-11-28 | The Public Health Research Institute Of The City Of New York, Inc. | Selection of target sites for antisense attack of rna |
| US20030170891A1 (en) | 2001-06-06 | 2003-09-11 | Mcswiggen James A. | RNA interference mediated inhibition of epidermal growth factor receptor gene expression using short interfering nucleic acid (siNA) |
| US20040209832A1 (en) | 2001-11-30 | 2004-10-21 | Mcswiggen James | RNA interference mediated inhibition of vascular endothelial growth factor and vascular endothelial growth factor receptor gene expression using short interfering nucleic acid (siNA) |
| JP2005500034A (ja) | 2001-06-20 | 2005-01-06 | プロション バイオテク リミテッド | 受容体型タンパク質チロシンキナーゼ活性化を遮断する抗体、そのスクリーニング方法、及びその使用 |
| DE60239962D1 (de) | 2001-08-14 | 2011-06-16 | Harvard College | Absolute quantifizierung von proteinen und modifizierten formen davon mittels mehrstufiger massenspektrometrie |
| US20030219839A1 (en) | 2001-09-20 | 2003-11-27 | Katherine Bowdish | Anti-PDGF antibodies and methods for producing engineered antibodies |
| US6734017B2 (en) | 2001-09-28 | 2004-05-11 | Isis Pharmaceuticals, Inc. | Antisense modulation of vascular endothelial growth factor receptor-2 expression |
| DE10230997A1 (de) | 2001-10-26 | 2003-07-17 | Ribopharma Ag | Medikament zur Erhöhung der Wirksamkeit eines Rezeptor-vermittelt Apoptose in Tumorzellen auslösenden Arzneimittels |
| PL375064A1 (en) | 2002-05-20 | 2005-11-14 | Abgenix, Inc. | Treatment of renal carcinoma using antibodies against the egfr |
| PT2314629E (pt) | 2002-07-18 | 2014-01-22 | Merus B V | Produção recombinante de misturas de anticorpos |
| US20040023390A1 (en) | 2002-08-05 | 2004-02-05 | Davidson Beverly L. | SiRNA-mediated gene silencing with viral vectors |
| CN1705753A (zh) * | 2002-09-30 | 2005-12-07 | 肿瘤疗法科学股份有限公司 | 非小细胞肺癌的诊断方法 |
| WO2004063355A2 (en) | 2003-01-10 | 2004-07-29 | Protein Design Labs, Inc. | Novel methods of diagnosis of metastatic cancer, compositions and methods of screening for modulators of matastatic cancer |
| JP2007528201A (ja) | 2003-03-14 | 2007-10-11 | ファルマシア・コーポレーション | 癌治療のためのｉｇｆ−ｉ受容体に対する抗体 |
| US20050214301A1 (en) | 2004-03-24 | 2005-09-29 | Cell Signaling Technology, Inc. | Antibodies specific for BCR-ABL fusion protein and uses thereof |
| EP1959955B1 (en) | 2005-12-05 | 2010-11-17 | Pfizer Products Inc. | Method of treating abnormal cell growth |
| WO2009051846A2 (en) * | 2007-10-18 | 2009-04-23 | Cell Signaling Technology, Inc. | Translocation and mutant ros kinase in human non-small cell lung carcinoma |
| US20100143918A1 (en) | 2007-01-19 | 2010-06-10 | Cell Signaling Technology, Inc. | Translocation and mutant ros kinase in human non-small cell lung carcinoma |
| SI2671954T1 (sl) | 2006-01-20 | 2018-11-30 | Cell Signaling Technology, Inc. | Translokacija in mutantna ROS kinaza v človeškem ne-drobnoceličnem karcinomu pljuč |
| US20120208824A1 (en) | 2006-01-20 | 2012-08-16 | Cell Signaling Technology, Inc. | ROS Kinase in Lung Cancer |
| US8383799B2 (en) | 2006-01-20 | 2013-02-26 | Cell Signaling Technology, Inc. | Translocation and mutant ROS kinase in human non-small cell lung carcinoma |
| PL2450437T3 (pl) | 2006-04-14 | 2017-12-29 | Cell Signaling Technology Inc | Defekty genu i zmutowana kinaza ALK w ludzkich guzach litych |
| CA2598893C (en) | 2006-10-11 | 2012-04-10 | Astellas Pharma Inc. | Eml4-alk fusion gene |
| US20110008347A1 (en) | 2006-12-01 | 2011-01-13 | Agency For Science ,Technology And Research | Cancer-related protein kinases |
| CN101466721B (zh) * | 2007-04-13 | 2013-08-21 | 细胞信号技术公司 | 在人实体瘤中的基因缺损和突变体alk激酶 |
| EP2255190A4 (en) | 2008-02-12 | 2011-05-04 | Brigham & Womens Hospital | FISH TEST FOR EML4-ALK FUSION IN LUNG CANCER |
| AU2010213578B2 (en) * | 2009-02-12 | 2015-01-29 | Cell Signaling Technology, Inc. | Mutant ROS expression in human cancer |
| GB2467901A (en) | 2009-02-12 | 2010-08-18 | Norgine Bv | 3',6'-dihydroxy-5(6)-nitrospiro[2-benzofuran-3,9'-xanthene]-1-one mixt. by reacting 4-nitrophthalic acid/anhydride & benzene-1,3-diol in methanesulphonic acid |
| HUE026647T2 (en) * | 2009-05-08 | 2016-07-28 | Astellas Pharma Inc | Diamino heterocyclic carboxamide compound |
| US20130288240A1 (en) * | 2010-05-21 | 2013-10-31 | Cell Signaling Technology, Inc. | Alk and ros kinase in cancer |
-
2011
- 2011-05-23 US US13/113,676 patent/US20120208824A1/en not_active Abandoned
-
2012
- 2012-05-23 SI SI201231545T patent/SI3182128T1/sl unknown
- 2012-05-23 TR TR2019/02690T patent/TR201902690T4/tr unknown
- 2012-05-23 EP EP18203673.1A patent/EP3492918B1/en active Active
- 2012-05-23 CA CA2841900A patent/CA2841900C/en active Active
- 2012-05-23 JP JP2014512072A patent/JP6210977B2/ja active Active
- 2012-05-23 EP EP12725976.0A patent/EP2715365B1/en active Active
- 2012-05-23 EP EP16196573.6A patent/EP3182128B1/en active Active
- 2012-05-23 CN CN201280036118.9A patent/CN103858011B/zh active Active
- 2012-05-23 DK DK12725976.0T patent/DK2715365T3/en active
- 2012-05-23 HU HUE16196573A patent/HUE041780T2/hu unknown
- 2012-05-23 CA CA3020650A patent/CA3020650C/en active Active
- 2012-05-23 PT PT16196573T patent/PT3182128T/pt unknown
- 2012-05-23 CN CN201610542647.6A patent/CN106148525B/zh active Active
- 2012-05-23 ES ES12725976.0T patent/ES2611281T3/es active Active
- 2012-05-23 ES ES16196573T patent/ES2716980T3/es active Active
- 2012-05-23 DK DK16196573.6T patent/DK3182128T3/en active
- 2012-05-23 KR KR1020137034188A patent/KR102123963B1/ko active Active
- 2012-05-23 WO PCT/US2012/039108 patent/WO2012162373A1/en not_active Ceased
-
2017
- 2017-09-11 JP JP2017173626A patent/JP6404423B2/ja active Active
-
2018
- 2018-05-31 US US15/994,165 patent/US11099188B2/en active Active
- 2018-09-11 JP JP2018169294A patent/JP6619070B2/ja active Active
-
2021
- 2021-07-16 US US17/377,475 patent/US20210349095A1/en not_active Abandoned
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| SI3182128T1 (sl) | Kinaza ros pri pljučnem raku | |
| GB2484598B (en) | Improvements in catheters | |
| PT2707030T (pt) | Tratamentos de cancro | |
| IL231426A0 (en) | Lung cancer biomarkers and their uses | |
| GB2505764B (en) | Improvements in dielectrics | |
| ZA201401527B (en) | Improvements in lockers | |
| SI2780332T1 (sl) | Morfolinilbenzotriazini za uporabo pri terapiji raka | |
| GB201208325D0 (en) | Saccharides | |
| SG11201500809WA (en) | Semi-submersible integrated port | |
| SG11201403144XA (en) | Improvements in coating technology | |
| IL238453A0 (en) | Trans-clomiphene for use in cancer treatment | |
| IL232713A0 (en) | erbb3 mutations in cancer | |
| HUE062128T2 (hu) | Hûtést érintõ fejlesztések | |
| GB201221387D0 (en) | Improvements in passive-stack ventilation | |
| GB201106630D0 (en) | Cancer therapy | |
| GB201205306D0 (en) | Improvements in awnings | |
| GB201203269D0 (en) | Improvements in awnings | |
| AU340371S (en) | 4P built in booth | |
| GB201100062D0 (en) | Improvements in ventilation | |
| GB201122332D0 (en) | My vault card | |
| GB201202593D0 (en) | All in one | |
| GB201118220D0 (en) | Cancer therapy | |
| GB201200389D0 (en) | Twinline skates | |
| GB201004712D0 (en) | Improvements in the chemotherapy of cancer | |
| GB201002199D0 (en) | Improvements in the chemotherapy of cancer |